Timothy F. Burns

Family Medicine

3815 N Schreiber Way Unit 102
Coeur D Alene, ID 83815

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 78 publications

CLO26-084: Prognostic Value of Sarcopenia in Patients With Metastatic NSCLC Receiving First-Line Immune Checkpoint Inhibitors.

CLO26-084: Prognostic Value of Sarcopenia in Patients With Metastatic NSCLC Receiving First-Line Immune Checkpoint Inhibitors.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 30, 2026

CLO26-114: Association Between Neoadjuvant Chemoimmunotherapy-Induced Anemia and Survival in Patients With Resectable Non-Small Cell Lung Cancer.

CLO26-114: Association Between Neoadjuvant Chemoimmunotherapy-Induced Anemia and Survival in Patients With Resectable Non-Small Cell Lung Cancer.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 30, 2026

SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC.

SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC.

Journal: Future oncology (London, England)

Published: April 06, 2026

CLO26-084: Prognostic Value of Sarcopenia in Patients With Metastatic NSCLC Receiving First-Line Immune Checkpoint Inhibitors.

CLO26-084: Prognostic Value of Sarcopenia in Patients With Metastatic NSCLC Receiving First-Line Immune Checkpoint Inhibitors.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 30, 2026

CLO26-114: Association Between Neoadjuvant Chemoimmunotherapy-Induced Anemia and Survival in Patients With Resectable Non-Small Cell Lung Cancer.

CLO26-114: Association Between Neoadjuvant Chemoimmunotherapy-Induced Anemia and Survival in Patients With Resectable Non-Small Cell Lung Cancer.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 30, 2026

Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth.

Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth.

Journal: Cancer cell

Published: February 11, 2026

Phase 2 study of cabozantinib (XL184) with nivolumab and ipilimumab for the treatment of poorly differentiated neuroendocrine carcinomas (ETCTN10315).

Phase 2 study of cabozantinib (XL184) with nivolumab and ipilimumab for the treatment of poorly differentiated neuroendocrine carcinomas (ETCTN10315).

Journal: The oncologist

Published: January 27, 2026

Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC.

Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: September 25, 2025

Time-Resolved Crystallography Reveals the Mechanisms of GTP hydrolysis for N-RAS and the Oncogenic Mutants G12C, G12V and Q61L.

Time-Resolved Crystallography Reveals the Mechanisms of GTP hydrolysis for N-RAS and the Oncogenic Mutants G12C, G12V and Q61L.

Journal: bioRxiv : the preprint server for biology

Published: September 02, 2025

Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study.

Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study.

Journal: Nature communications

Published: July 28, 2025

Advanced hierarchical computational modeling-based rational development of platinum (II) nanocomplex to improve lung cancer therapy.

Advanced hierarchical computational modeling-based rational development of platinum (II) nanocomplex to improve lung cancer therapy.

Journal: Advanced functional materials

Published: June 02, 2025

Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938).

Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938).

Journal: Cancer

Published: May 21, 2025

Showing 1-12 of 78

Last Updated: 09/26/2026